ARS Pharmaceuticals, Inc. SPRY Earnings yield
Earnings yield at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s earnings yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s earnings yield?
- ARS Pharmaceuticals, Inc. (SPRY) reported earnings yield of -24.8% in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s earnings yield changed year-over-year?
- ARS Pharmaceuticals, Inc.'s earnings yield decreased by 1858.3% year-over-year, from -1.3% to -24.8%.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s earnings yield?
- Over 4 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s earnings yield has grown at a 64.1% compound annual growth rate (CAGR), from -2% to -14.9%.
- What does earnings yield mean?
- Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.